Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024

• 2025

  Log in to bookmark this resource.

  Log in
• Karen Jacobson; Andrew Watson; Maqdooda Merchant; Bruce Fireman; Ousseny Zerbo; Nicola Klein
PMID: 39775810DOI: https://doi.org/10.1001/jamanetworkopen.2024.53696

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

The article investigates the uptake of maternal RSV vaccination and infant nirsevimab among infants born from October 2023 to March 2024 within Kaiser Permanente Northern California. Findings reveal that nearly 80% of infants received RSV protection, with variations based on maternal age and race. Most infants born before December received nirsevimab, while those born after October 25 were exposed to maternal RSVpreF. Infants of younger and Black mothers had lower RSV protection coverage, mainly due to differences in maternal RSVpreF vaccination. The study suggests that having both protection methods available in sufficient supply may help reduce disparities in infant RSV protection.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Cohort Studies; Infant, Newborn; Maternal Health Services; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious; Respiratory Syncytial Virus Infections; Vaccination; Respiratory Syncytial Virus Vaccines; Electronic Health Records; Health Disparate Minority and Vulnerable Populations; Sociodemographic Factors

Institutions: Kaiser Permanente

---

More like this

Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024 2025 · Kaiser Permanente Effectiveness of Nirsevimab in Infants Against Respiratory Syncytial Virus and Related Events 2024 · Kaiser Permanente Healthcare Providers' and Pregnant People's Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus 2024 · Oracle Life Sciences, Pfizer Inc.

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---